QALY
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation
UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …
NICE is ‘setting prices too high’ for NHS
February 19, 2015Sales and Marketing ABPI, NHS, NICE, QALY, costs, health, pharma
The cost threshold NICE uses when approving drugs is too high and is doing more harm than good, new research …
ABPI president: NICE needs political reform
June 17, 2014Business Services, Medical Communications, Research and Development ABPI, NHS, NICE, Pfizer, QALY, emms, jonathan, vba
NICE needs to be reformed with its QALY formula heavily revised if it is to meet the challenges of 21st …
NICE: new system will allow more drugs on NHS
February 17, 2014Sales and Marketing DH, Dillon, DoH, NHS, NICE, QALY
NICE has said that it will be able to approve more medicines under a new drug pricing policy, but warns …
NICE hits back at ‘limited’ EC study
January 28, 2013Sales and Marketing ABPI, EC, NHS, NICE, QALY, Whitehead
NICE has delivered a robust defence of the methods by which it arrives at a judgment on the value of …
NICE: ‘lot of work’ to do on VBP
November 30, 2012Medical Communications, Sales and Marketing Boysen, NHS, NICE, QALY, VBP
NICE is still working out what its role with the new NHS Commissioning Board will be, with other key issues …
NICE bows to industry pressure
August 21, 2012Sales and Marketing ABPI, NICE, QALY, VBP
NICE has bowed to industry pressure and will allow independent advisors to sit on its appeals board. An appeal can …
NICE still minded not to recommend Zelboraf
August 9, 2012Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf
NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …
Health Bill continues fast pace of NHS reform
January 20, 2011Sales and Marketing GP consortia, NHS, NHS Commissioning Board, NHS reforms, NICE, QALY
The government has outlined its draft Health and Social Care Bill, making some minor concessions to critics but promising no …
NICE ‘surprised’ at downgrading of its role
November 5, 2010Sales and Marketing Andrew Dillon, GP prescribing deicisions, NICE, QALY, incremental cost-effectiveness ratio, value-based pricing
NICE received no warning that its health technology assessment role is to be downgraded, the watchdog’s head has admitted. In …
Latest content
FibroFind appoints Lee Borthwick as CEO
